ALS News & Research For postings of news or research links and articles related to ALS


advertisement
Reply
 
Thread Tools Display Modes
Old 01-25-2008, 09:14 AM #1
BobbyB's Avatar
BobbyB BobbyB is offline
In Remembrance
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
BobbyB BobbyB is offline
In Remembrance
BobbyB's Avatar
 
Join Date: Aug 2006
Location: North Carolina
Posts: 4,609
15 yr Member
Thumbs Up U of I study finds drug prolongs life of mice with ALS

U of I study finds drug prolongs life of mice with ALS
By TONY LEYS • REGISTER STAFF WRITER • January 25, 2008


University of Iowa researchers say they've found a drug that doubles the life span of mice suffering from a form of Lou Gehrig's disease.

The scientists caution that the drug has been tried only on animals with a relatively rare, inherited version of the disease, and they're not sure it would help humans. On the other hand, they say the discovery could be a major step toward a treatment for people afflicted with the condition.

Lou Gehrig's, also known as amyotrophic lateral sclerosis, is a degenerative, fatal nerve disease that strikes 5,600 Americans per year. It causes them to lose muscle control, eventually leaving them unable to breathe.


The U of I researchers make up one of numerous teams investigating the disease's causes and proposing treatments.

Biology professor John Engelhardt, who helped lead the study, said the drug is a purified form of apocynin, a plant extract that is used in some nutritional supplements. He said the team hopes to start testing the drug for safety in humans within three years, and to study whether it also might help people who have the more common, "sporadic" form of the disease.

Engelhardt said the experiments indicate the drug slows the disease's progress, but doesn't reverse it.

"There is a very significant correlation between how early you get on the drug and how long you live - if you're a mouse," he said. If the results translate to humans, people would have an incentive to be tested early, so they could start taking the drug before symptoms appear.

The U of I study looks only at mice with an inherited form of the disease, which accounts for about 2 percent of human cases. The researchers reported last fall that they managed to double the life span of such mice by manipulating their genes. Such genetic treatment is complicated and could be dangerous, and the scientists did not believe it would be practical in humans.

In the new study, the researchers say they've managed to produce the same results by using a drug to dampen the influence of the problem gene. The experiment showed that mice that drank water laced with the drug lived about 250 days, twice as long as untreated mice.

The study was published Thursday in the Journal of Clinical Investigation. The 12-page paper is complicated, even as these sorts of things go. But the gist of it is that the drug helps control production of "reactive oxygen species," such as hydrogen peroxide, in cells of mice bred to have the disease. The molecules are naturally occurring substances that are necessary for life, but they can be toxic in large quantities. Researchers believe that people with certain inherited forms of Lou Gehrig's disease produce too many of the molecules, which can lead to inflammation and death of nerve cells.

A national expert who expressed caution about the U of I's earlier study called the new results "very promising."

Dr. Lucie Bruijn, science director of the ALS Association, said the study appears to break new ground.

"I'm extremely enthusiastic," she said. "I think the group is teasing out a new and interesting pathway."

However, Bruijn warned that ALS patients should not rush out and buy dietary supplements with apocynin.

"They would be crazy to do that," she said. "I would be very cautious."

She acknowledged that many ALS patients are desperate because they have few good options to fight the fatal disease. But she said tests could show that apocynin causes dangerous side effects, including eye damage.

Bruijn said she hopes to see other teams replicate the U of I study. She also said it's unclear whether the drug would help people who have the more common form of the disease. The main obstacle to answering that question, Bruijn said, is scientists have been unable to develop mice with the common form of ALS.

Reporter Tony Leys can be reached at (515) 284-8449 or tleys@dmreg.com

http://www.desmoinesregister.com/app...87/-1/SPORTS01
__________________

.

ALS/MND Registry

.
BobbyB is offline   Reply With QuoteReply With Quote

advertisement
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
New Study Finds Blood-Spinal Cord Barrier Compromised In Mice With ALS BobbyB ALS News & Research 1 11-21-2007 07:28 AM
Noninvasive Ventilation Prolongs Life in ALS lisag ALS 0 10-12-2006 08:06 AM


All times are GMT -5. The time now is 08:32 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.